Health, Scioscia (UniFg): Severe Asthma, with Mepolizumab Remission up to 3 Years
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.5 Articles
5 Articles
Calabria News
Giornale RadioIn severe asthma, biological therapy with mepolizumab "consists a change in the history of the disease, because we go to act on the epithelium and remodelling. By blocking interleukin 5 we go to block both the upstream mechanisms upstream, "until we reach the epithelium, and all the downstream mechanisms" and then downstream, "retarding basically the migration of eosinophils and [...] L'articolo Farmaci, Scioscia (UniFg): "With mepolizumab carri…
Rec News | Lontani dal mainstream
With mepolizumab we have clinical efficacy data not only at 12 months but also longitudinal data, with the study of Bagnasco, up to 3 years. Early intercepting patients with a T2 phenotype and with characteristics such as the presence of mucus caps or the compromise of the small airways allows to obtain a result [...] The article Health, Scioscia (UniFg): Severe asthma, with mepolizumab remission up to 3 years is from Rec News.
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
